Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

Open access

Abstract

Background Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil. We investigated the efficacy of these two agents combined for first-line treatment of metastatic colorectal cancer.Methods 387 patients previously untreated with chemotherapy (other than adjuvant) for advanced colorectal cancer were randomly assigned open-label irinotecan plus fluorouracil and calcium folinate (irinotecan group, n=199) or fluorouracil and calcium folinate alone (no-irinotecan group, n=188). Infusion schedules were once weekly or every 2 weeks, and were chosen by each centre. We assessed response rates and time to progression, and also response duration, survival, and quality of life. Analyses were done on the intention-to-treat population and on evaluable patients.Findings The response rate was significantly higher in patients in the irinotecan group than in those in the no-irinotecan group (49 vs 31%, p<0.001 for evaluable patients, 35 vs 22%, p<0.005 by intention to treat). Time to progression was significantly longer in the irinotecan group than in the no-irinotecan group (median 6.7 vs 4.4 months, p<0.001), and overall survival was higher (median 17.4 vs 14.1 months, p=0.031). Some grade 3 and 4 toxic effects were significantly more frequent in the irinotecan group than in the no-irinotecan group, but effects were predictible, reversible, non-cumulative, and manageable.Interpretation Irinotecan combined with fluorouracil and calcium folinate was well-tolerated and increased response rate, time to progression, and survival, with a later deterioration in quality of life. This combination should be considered as a reference first-line treatment for metastatic colorectal cancer.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(00)02034-1

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 19 references

Research works printed but not linked: 6

  1. Fages, 1997, Tumour response and stabilization rates are worthwhile surrogate endpoints in metastatic colorectal cancer: analysis of data in 455 fluorouracil-resistant patients treated with irinotecan, Proc ASCO, 16
  2. Izzo, 1992, Low dose fluorouracil continuous infusion (FuCI) in advanced colorectal cancer (ACC): clinical evidence for reversal of acquired intrinsic resistance to fluorouracil or fluorouracil folinic acid (FuFo), Proc AACR, 33, 217
  3. D'Arpa, 1989, Topoisomerase-targetting antitumour drugs, Biochim Biophys Acta, 989, 163
  4. De Gramont, 1998, Homerin. A randomized trial of leucovorin and 5-FU with or without oxaliplatin in advanced colorectal cancer, Proc ASCO, 17, 985
  5. Giachetti, 1997, Phase III trial of 5-fluorouracil (5-FU), folinic acid (FA) with or without oxaliplatin (OXA) in previously untreated patients with metastatic colorectal cancer, Proc ASCO, 16, 229
  6. Saltz, 1999, Weekly irinotecan (CPT-11), leucovorin (LV), and fluorouracil (FU) is superior to daily X5 LV/FU in patients (PTS with previously untreated matastatic colorectal cancer (CRC), Proc ASCO, 18, 233

Cited by

See all 3,256

Metadata

Authors
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., Gruia, G., Awad, L., & Rougier, P.
Affiliations
  • Royal Marsden Hospital (GB)
  • Duran i Reynals Hospital (ES)
  • Maidstone Hospital (GB)
  • Royal South Hants Hospital (GB)
  • Nottingham City Hospital (GB)
  • Hôpital Ambroise-Paré (FR)
Corresponding author
Douillard, JY
Venue
The Lancet
Publisher
Elsevier BV
Published
2000-03
Volume
355
Issue
9209
Pages
1041-1047
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2128447158
Cited by
3,256
References
19
Citations by year
2026: 20 · 2025: 34 · 2024: 48 · 2023: 71 · 2022: 94 · 2021: 70 · 2020: 65 · 2019: 81 · 2018: 82 · 2017: 96 · 2016: 108 · 2015: 117 · 2014: 121 · 2013: 119 · 2012: 126
FWCI
69.62
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords
irinotecan, 5-fluorouracil, leucovorin, metastatic colorectal cancer, first-line chemotherapy, combination chemotherapy, response rate, time to progression, overall survival, chemotherapy toxicity, quality of life
MeSH terms
Irinotecan, Adenocarcinoma, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Phytogenic, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Staging, Quality of Life, Colorectal Neoplasms, Survival Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. https://app.cochat.ai/papers/10.1016/s0140-6736(00)02034-1
The paper
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., Gruia, G., Awad, L., & Rougier, P. (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. The Lancet. https://doi.org/10.1016/s0140-6736(00)02034-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.